ABOUT
HYACORP
Founded in 2006 by the German pioneer Bioscience, HYAcorp is a range of hyaluronic acid dermal fillers that restore volume and contour the face and body. It offers a wide range of specialized applications with varying degrees of cross linking, particle size, and concentration of hyaluronic acid.
ABOUT
BIOSCIENCE GMBH
BioScience GmbH is a German Laboratory founded in 2001 with the vision to empower and inspire aesthetic professionals and patients with our high-performance hyaluronic acid medical devices, injectables, and skincare products. Bioscience GmbH is the platinum sponsor of the International Society of Aesthetic Plastic Surgery (ISAPS) – the world’s leading professional body for board-certified aesthetic plastic surgeons. Present since 2006 in medical aesthetics, the company offers both monophasic and biphasic hyaluronic acid and CE certified supplier of dermal fillers for the face and body through its 2 recognized brands: HYAcorp and Genefill.
BIPHASIC DERMAL FILLERS
HYAcorp is a pioneer in the production of biphasic dermal fillers. HYAcorp Fillers consist of cross-linked HA particles suspended in non cross-linked Hyaluronic Acid. Biphasic filler take more time to be degraded by your body, providing a more long lasting result.
BDDE FREE*
Due to our advanced technology our dermal fillers have no free BDDE particles in their composition, presenting a toxicity level lower than the more strict standards around the world.
*A residual level of unreacted BDDE of <2ppm has been considered safe in a FDA risk assessment report (see STED.6.3.7.1). The specification of HYAcorp is <0,001 mg/ml.
BIPHASIC DERMAL FILLERS
HYAcorp is a pioneer in the production of biphasic dermal fillers. HYAcorp Fillers consist of cross-linked HA particles suspended in non cross-linked Hyaluronic Acid. Biphasic filler take more time to be degraded by your body, providing a more long lasting result.
BDDE FREE*
Due to our advanced technology our dermal fillers have no free BDDE particles in their composition, presenting a toxicity level lower than the more strict standards around the world.
*A residual level of unreacted BDDE of <2ppm has been considered safe in a FDA risk assessment report (see STED.6.3.7.1). The specification of HYAcorp is <0,001 mg/ml.